Int. J. Med. Sci. 2017, Vol. 14
Ivyspring
International Publisher
615
International Journal of Medical Sciences 2017; 14(7): 615-621. doi: 10.7150/ijms.19213
Research Paper
Systematic Evaluation of Corticosteroid Use in Obese and Non-obese Individuals: A Multi-cohort Study Mesut Savas1, 2, Vincent L. Wester1, 2, Sabine M. Staufenbiel1, 2, Jan W. Koper1, 2, Erica L.T. van den Akker1, 3, Jenny A. Visser1, 2, Aart J. van der Lely1, 2, Brenda W.J.H. Penninx4, Elisabeth F.C. van Rossum1, 2, 5 1. 2. 3. 4. 5.
Obesity Center CGG (Centrum Gezond Gewicht), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands; Lifelines Cohort Study and Biobank, Groningen, The Netherlands.
Corresponding author: Elisabeth F.C. van Rossum, MD PhD, Internist-endocrinologist / Professor of Medicine, Head of Obesity Center CGG (Centrum Gezond Gewicht). Erasmus MC, University Medical Center Rotterdam, Room D-428. P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Phone: +31 10 703 39 72, Fax: +31 10 703 47 68, E-mail: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Received: 2017.01.16; Accepted: 2017.03.15; Published: 2017.06.13
Abstract Background: Although the use of corticosteroids has been linked to high incidence of weight gain, no data are available concerning the differences in corticosteroid use between a diverse obese population and non-obese individuals. The main purpose of this study was to systematically explore the use of corticosteroids in obese subjects compared to non-obese controls. In addition, we also explored self-reported marked weight gain within obese subjects. Methods: Two hundred seventy-four obese outpatients (median [range] BMI: 40.1 kg/m2 [30.5-67.0]), and 526 non-obese controls (BMI: 24.1 kg/m2 [18.6-29.9]) from two different Dutch cohort studies were included. Corticosteroid use at the time of clinic or research site visit for up to the preceding three months was recorded in detail. Medical records and clinical data were evaluated with regard to age and body mass index in relation to corticosteroid use, single or multiple type use, and administration forms. Results: Recent corticosteroid use was nearly twice as high for obese subjects than for non-obese controls (27.0% vs. 11.9% and 14.8%, both P
Ivyspring
International Publisher
615
International Journal of Medical Sciences 2017; 14(7): 615-621. doi: 10.7150/ijms.19213
Research Paper
Systematic Evaluation of Corticosteroid Use in Obese and Non-obese Individuals: A Multi-cohort Study Mesut Savas1, 2, Vincent L. Wester1, 2, Sabine M. Staufenbiel1, 2, Jan W. Koper1, 2, Erica L.T. van den Akker1, 3, Jenny A. Visser1, 2, Aart J. van der Lely1, 2, Brenda W.J.H. Penninx4, Elisabeth F.C. van Rossum1, 2, 5 1. 2. 3. 4. 5.
Obesity Center CGG (Centrum Gezond Gewicht), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands; Lifelines Cohort Study and Biobank, Groningen, The Netherlands.
Corresponding author: Elisabeth F.C. van Rossum, MD PhD, Internist-endocrinologist / Professor of Medicine, Head of Obesity Center CGG (Centrum Gezond Gewicht). Erasmus MC, University Medical Center Rotterdam, Room D-428. P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Phone: +31 10 703 39 72, Fax: +31 10 703 47 68, E-mail: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Received: 2017.01.16; Accepted: 2017.03.15; Published: 2017.06.13
Abstract Background: Although the use of corticosteroids has been linked to high incidence of weight gain, no data are available concerning the differences in corticosteroid use between a diverse obese population and non-obese individuals. The main purpose of this study was to systematically explore the use of corticosteroids in obese subjects compared to non-obese controls. In addition, we also explored self-reported marked weight gain within obese subjects. Methods: Two hundred seventy-four obese outpatients (median [range] BMI: 40.1 kg/m2 [30.5-67.0]), and 526 non-obese controls (BMI: 24.1 kg/m2 [18.6-29.9]) from two different Dutch cohort studies were included. Corticosteroid use at the time of clinic or research site visit for up to the preceding three months was recorded in detail. Medical records and clinical data were evaluated with regard to age and body mass index in relation to corticosteroid use, single or multiple type use, and administration forms. Results: Recent corticosteroid use was nearly twice as high for obese subjects than for non-obese controls (27.0% vs. 11.9% and 14.8%, both P
